2027 Program

Monday, March 1, 2027

7:30 - 8:15 am
Breakfast Workshop | Option #1 | In-Person & Virtual 

"Case-based Vaccine-Preventable Diseases Discussion"

Adam Ratner, MD
  • Describe the epidemiology of vaccine-preventable diseases relevant to pediatric practice 
  • Discuss clinical presentations, differential diagnosis, practical testing strategies, and treatment for selected vaccine-preventable diseases 
7:30 - 8:15 am

Breakfast Workshop | Option #2 | In-Person 

(Held in conference rooms: D, E & F)


“What to Do About a Limping Child”


John P. Whelan, MD, PhD

 


8:15 - 8:30 am

BREAK (Please visit our exhibits in the Resort Foyer)


8:30 - 8:40 am
ANNOUNCEMENTS
PLENARY SESSIONS: (Held in conference rooms: D, E & F)

8:40 - 9:20 am

Updates in the Genetic Evaluation of Intellectual Disability"


Derek Neilson, MD

 

  • Describe current genetic testing modalities 


  • Review the 2025 AAP guidelines for genetic evaluation of intellectual disability or global developmental delay 



9:20 - 10 a.m.

"Hot Topics in Pediatric Infectious Diseases"


Monica Abd El Nour, MD, MSCI

 

  • Review three hot topics in pediatric infectious diseases based on ongoing outbreaks and circulating infections 



10:00 - 10:20 a.m.

BREAK (Please visit our exhibits in the Resort Foyer)


 10:20 - 11:00 am

“The New AAP UTI Guidelines: The Evidence & The Controversy, Part 1"


Brian Alverson, MD

 

  • Apply the 2026 AAP guideline recommendations to the evaluation and diagnosis of children with suspected urinary tract infection 
  • Interpret urinalysis and urine culture results using the evidence supporting the updated diagnostic criteria 
  • Select appropriate antimicrobial therapy based on patient age, illness severity, and the guideline recommendations regarding antibiotic route and duration 



 11:00 - 11:40 am

"The Modern Evaluation of Hypermobility and the Related Monogenic Connective Tissue Diseases"


John P. Whelan, MD, PhD



 11:40 am - 12:20 pm

"Rethinking Rescue: SMART & AIR in Pediatric Asthma, from Evidence to Practice"


Christina Kwong, MD

 

  • Describe the shift from short-acting beta-agonist (SABA)-based rescue to anti-inflammatory reliever strategies in pediatric asthma. 


  • Identify the indications for single maintenance and reliever therapy (SMART) and anti-inflammatory reliever (AIR) therapy across age groups and asthma severities. 


  • Review practical strategies for implementing SMART and AIR therapy.